3.15
Newcelx Ltd Aktie (NCEL) Neueste Nachrichten
NCEL Stock Price, Quote & Chart | NEWCELX LTD (NASDAQ:NCEL) - ChartMill
Exclusive: NewcelX eyes accelerated 2026 execution for diabetes drug - MSN
[EFFECT] NewcelX Ltd. SEC Filing - Stock Titan
NCEL Should I Buy - Intellectia AI
TradingKey - TradingKey
NewcelX (NASDAQ: NCEL) registers 2.26M shares for resale by investors - Stock Titan
Why NewcelX (NCEL) is still under the radar (Risk Aversion) 2026-05-06Top Analyst Buy Signals - Newser
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares - Quantisnow
NewcelX Ltd. (NCEL) updates resale prospectus for up to 500,000 shares - Stock Titan
How NewcelX (NCEL) differentiates itself from competitors (Investor Concern) 2026-05-05High Interest Stocks - newser.com
Julien Ruggieri Discloses Investment at NewcelX Ltd. with 25.3% Stake - TradingView
League Jinn holds 25.3% ownership stake in NewcelX (NCEL) - Stock Titan
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - Yahoo Finance
NLSPW SEC FilingsNEWCELX LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Olivier Samuel Buys Handful Of Shares In NewcelX - 富途牛牛
Despite NewcelX's Pullback, Insiders Still Gained ₪136k - Yahoo Finance
NewcelX Loses US$2.3m Market Value But Insiders See Windfall Of ₪136k - simplywall.st
NCEL | NewcelX Ltd. Ordinary Shares Insider Trading - Quiver Quantitative
NewcelX Ltd. announced that it has received $1.349994 million in funding - marketscreener.com
NCEL - Finviz
NewcelX Posts 2025 Results and Bolsters Funding to Accelerate Type 1 Diabetes Program - TipRanks
Newcelx Reports Financial Results for 2025 an - Moomoo
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - The Manila Times
NewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth Plans - Quiver Quantitative
NewcelX makes Type 1 diabetes program its 2026 flagship - Stock Titan
Insider Buying: Olivier Samuel Acquires 81,818 Shares of NewcelX Ltd (NCEL) - GuruFocus
NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NewcelX (NCEL) 20-F: Kadimastem merger, heavy losses and funding risk - Stock Titan
NewcelX Ltd. (NCEL) Stock Price Today - MEXC Exchange
NewcelX (NCEL) Trend Analysis | Q1 2025: Earnings ReportDividend Report - Cổng thông tin điện tử tỉnh Lào Cai
NewcelX updates presentation on diabetes therapy collaboration By Investing.com - Investing.com India
Newcelx updates corporate presentation to highlight type 1 diabetes flagship program - marketscreener.com
NewcelX Highlights Type 1 Diabetes Flagship and Eledon Collaboration in Updated April 2026 Presentation - TipRanks
NewcelX updates presentation on diabetes therapy collaboration - Investing.com
NewcelX Ltd. Enhances Type 1 Diabetes Program with Strategic Collaboration with Eledon Pharmaceuticals - Quiver Quantitative
[6-K] NewcelX Ltd. Current Report (Foreign Issuer) | NCEL SEC FilingForm 6-K - Stock Titan
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - The Manila Times
NewcelX heads to Swiss Biotech with a Type 1 diabetes strategy - Stock Titan
NewcelX (NCEL) Stock Equalweight (Runs Up) 2026-04-18High Interest Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Liora Oren Net Worth (2026) - GuruFocus
Eran Israel Iohan Net Worth (2026) - GuruFocus
Olivier Samuel Net Worth (2026) - GuruFocus
Tamar Galili Net Worth (2026) - GuruFocus
Alexander Zwyer Net Worth (2026) - GuruFocus
Ronen Twito Net Worth (2026) - GuruFocus
Kfir Molakandov Net Worth (2026) - GuruFocus
Michel Revel Net Worth (2026) - GuruFocus
Omri Hagai Net Worth (2026) - GuruFocus
Should I Buy NewcelX (NCEL) Stock Now | Price at $2.58, Up 3.61%Put Spread Alert - Newser
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):